Orthocell’s June Quarter Revenue Climbs 22.8% to $2.73 Million
Orthocell Limited has posted a record quarterly revenue of A$2.73 million, driven by strong Australian sales of its nerve repair product Remplir™, with US market expansion poised to accelerate in FY26.
- Record quarterly revenue of A$2.73 million, up 22.8% from prior quarter
- Strong Remplir™ sales in Australia underpin growth
- US commercial rollout underway with first surgical use completed
- 14 US distributors appointed covering 25 states
- Robust balance sheet with A$28.5 million cash and no debt
Record Revenue Milestone
Orthocell Limited (ASX, OCC), a regenerative medicine company specialising in nerve repair, has announced a new quarterly revenue record of A$2.73 million for the June 2025 quarter. This marks a 22.8% increase over the previous quarter’s record of A$2.22 million, continuing a consistent upward trajectory in sales driven primarily by its flagship product, Remplir™.
Remplir™, a collagen wrap designed to improve outcomes in peripheral nerve repair surgeries, has gained significant traction in the Australian market. The product is now used by over 200 surgeons across more than 165 hospitals, reflecting growing surgeon confidence in its ability to deliver superior and predictable nerve regeneration results.
US Market Expansion on the Horizon
While the recent revenue record excludes contributions from the United States, Orthocell is preparing for a major commercial push in this lucrative market. The company recently completed the first surgical use of Remplir™ in the US, a critical milestone following FDA clearance. This step is expected to accelerate adoption as surgeons gain experience with the product.
Orthocell has appointed 14 specialist nerve distributors across 25 US states, establishing a robust network to support sales growth. The US nerve repair market is estimated at US$1.6 billion, presenting a substantial opportunity for expansion. The company anticipates that US sales will ramp up significantly during the first half of FY26, complementing its strong Australian performance.
Financial Strength and Strategic Outlook
Orthocell’s financial position remains solid, with approximately A$28.5 million in cash and no debt. This strong balance sheet provides the company with the flexibility to invest in broadening its commercial footprint and accelerating revenue growth in existing and new markets.
CEO Paul Anderson highlighted the significance of the milestone, stating that the record revenue underscores the market’s positive response to Orthocell’s products and sets a strong foundation for US expansion. The company’s commercialisation strategy in Australia is proving effective and is expected to be replicated on a larger scale in the US.
Looking ahead, Orthocell is well positioned to capitalise on the global nerve repair market, estimated to exceed US$3.5 billion, with ongoing product development and regulatory progress supporting its growth ambitions.
Bottom Line?
Orthocell’s record revenue and US rollout set the stage for a pivotal growth phase in FY26.
Questions in the middle?
- How quickly will US Remplir™ sales ramp up and impact overall revenue?
- What are the key challenges in scaling distribution across the US market?
- How will Orthocell’s pipeline products contribute to future growth beyond Remplir™?
